[Skip to Navigation]
Sign In
November 2018

Errors in Number at Risk and Author Email Address

JAMA Oncol. 2018;4(11):1625. doi:10.1001/jamaoncol.2018.5345

In the Original Investigation titled “Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial,”1 published in JAMA Oncology, there was an error in Figure 2. In panel B, the number at risk of 249 should have been 294. In addition, the Corresponding Author email has been updated. The article has been corrected online.

Han  B, Li  K, Wang  Q,  et al.  Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 clinical trial  [published online August 9, 2018].  JAMA Oncol. doi:10.1001/jamaoncol.2018.3039Google Scholar